Epithelial ovarian cancer: Influence of polymorphism at the glutathione S-transferase GSTM1 and GSTT1 loci on p53 expression

British Journal of Cancer

Volumn 74, Issue 11, 1996, Pages 1757-1761

  Sarhanis, P ^a   Redman, C ^a   Perrett, C ^a   Brannigan, K ^a   Clayton, R N ^a   Hand, P ^b   Musgrove, C ^b   Suarez, V ^c   Jones, P ^a   Fryer, A A ^a   Farrell, W E ^a   Strange, R C ^a,d  

^a KEELE UNIVERSITY   (United Kingdom)

^b UNIVERSITY HOSPITAL OF NORTH STAFFORDSHIRE   (United Kingdom)

^c STAFFORDSHIRE GENERAL HOSPITAL   (United Kingdom)

^d KEELE UNIVERSITY SCHOOL OF MEDICINE   (United Kingdom)

Author keywords

Genetic predisposition; GSTM1; GSTT1; Ovarian cancer; p53

Indexed keywords

CELL DNA; CYTOCHROME P450; GLUTATHIONE TRANSFERASE; PROTEIN P53;

ADULT; ARTICLE; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; DETOXIFICATION; DNA POLYMORPHISM; ELECTROPHORETIC MOBILITY; EPITHELIUM CELL; EXON; FEMALE; GENE DELETION; GENE LOCUS; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CANCER; OXIDATIVE STRESS; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE STRAND CONFORMATION POLYMORPHISM;

EID: 10544248587     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.626     Document Type: Article

References (20)

1. BELL DA, TAYLOR JA, PAULSON DF, ROBERTSON CN, MOHLER JL AND LUCIER GW. (1993). Genetic risk and carcinogen exposure: a common inherited defect of the carcinogen-metabolism gene glutathione S-transferase M1 (GSTM1) that increases susceptibility to bladder cancer. J. Natl Cancer Inst., 85, 1159-1164.
2. CLAYTON L, HILEY C, DAVIES SJ, D'SOUZA RJ, JONES P, STRANGE RC AND ABER GM. (1992). Glomerular injury induced by hydrogen peroxide: modifying influence of ACE inhibitors. Free Rad. Res. Commun., 17, 271-278.
3. DEAKIN M, ELDER J, HENDRICKSE C, PECKHAM D, BALDWIN D, PANTIN C, WILD N, LEOPARD P, BELL D, JONES P, DUNCAN H, BRANNIGAN K, ALLDERSEA J, FRYER A AND STRANGE R. (1996). Glutathione S-transferase GSTT1 phenotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis, 17, 881-884.
4. ECCLES D, BRETT L, LESSELS A, GRUBER L, LANE D, STEEL CM AND LEONARD RC. (1992a). Overexpression of the p53 protein and allele loss at 17p13 in ovarian carcinoma. Br. J. Cancer, 65, 40-45.
5. ECCLES DM, RUSSELL SE, HAITES NE, ATKINSON R, BELL DW, GRUBER L, HICKEY I, KELLY K, KITCHENER H AND LEONARD R. (1992b). Early loss of heterozygosity on 17q in ovarian cancer. Oncogene, 7, 2069-2072.
6. ELEXPURU-CAMIRUAGA J, BUXTON N, KANDULA V, DIAS VS, CAMPBELL D, MCINTOSH J, BROOME J, JONES P, INSKIP A, ALLDERSEA J, FRYER AA AND STRANGE RC. (1995). Susceptibility to astrocytoma and meningioma: influence of allelism of glutathione S-transferase, GSTT1 and GSTM1 and cytochrome P450, CYP2D6 loci. Cancer Res., 55, 4237-4239.
7. GOODWIN AK, TESTA JR AND HAMILTON TC. (1993). The biology of ovarian cancer development. Cancer, 71, 530-536.
8. GREENBLAT MS, BENNETT WP, HOLLSTEIN M AND HARRIS CC, (1994). Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54, 4855-4878.
9. HEAGERTY AHM, FITZGERALD D, SMITH A, BOWERS B, JONES P, FRYER A, ZHAO L, ALLDERSEA J AND STRANGE RC. (1994). Glutathione S-transferase GSTM1 phenotypes and protection against cutaneous malignancy. Lancet, 343, 266-268.
10. HEAGERTY A, SMITH A, ENGLISH J, LEAR J, PERKINS W, BOWERS B, JONES P, GILFORD J, ALLDERSEA J, FRYER AA AND STRANGE RC. (1996). Susceptibility to multiple cutaneous basal cell carcinomas: significant interactions between glutathione S-transferase GSTM 1 genotypes, skin type and male gender. Br. J. Cancer, 73, 44-48.
11. NEBERT DW. (1994). Drug-metabolizing enzymes in ligand-modulated transcription. Biochem. Pharmacol., 47, 25-37.
12. - autoantibody profile in patients with systemic lupus erythematosus. Arthritis Rheumatism, (in press).
13. PERRETT CW, CLAYTON RN, PISTORELLO M, BOSCARO M, SCANARINI M, BATES AS, BUCKLEY N, JONES P, FRYER AA, GILFORD J, ALLDERSEA J AND STRANGE RC (1995). GSTM1 and CYP2D6 genotype frequencies in patients with pituitary tumours: Effects on p53, ras and gsp. Carcinogenesis, 16, 1643-1645.
14. RYBERG D, KURE K, LYSTAD S, SKAUG V, STANGELAND L, MERCY I, BORRESEN A-L AND HAUGAN A. (1994). p53 mutations in lung tumours: relationship to putative susceptibility markers for cancer. Cancer Res., 54, 1551-1555.
15. SHEPHERD JH. (1989). Revised FIGO staging for gynaecological cancer. Br. J. Obstet. Gynaecol., 96, 889-892.
16. SHERIDAN E, SILCOCKS P, SMITH J, HANCOCK BW AND GOYNS MH. (1994). P53 mutations in a series of epithelial ovarian cancers from the UK and its prognostic significance. Eur. J. Cancer, 30A, 1701-1704.
17. SMITH G, STANLEY LA, SIM E, STRANGE RC AND WOLF CR. (1995). Metabolic polymorphism and cancer susceptibility. Cancer Surveys, 25, 27-65.
18. SPRAGG RG. (1991). DNA strand break formation following exposure of bovine pulmonary artery and aortic endothelial cells to reactive oxygen products. Am. J. Resp. Cell. Mol. Biol., 4, 4-10.
19. STRANGE RC. (1996). Glutathione S-transferases and cancer susceptibility. In Glutathoine S-transferase Structure Function and Clinical Implication. Vermeulen NPE, Mulder GJ, Nieuwenhuyse H, Peters WHM and Van Bladeren PJ (eds) pp.239-247. Taylor and Francis: Salisbury.
20. WOLF CR, SMITH CA, GOUGH AC, MOSS JE, VALLIS KA, HOWARD G, CAREY FJ, MILLS K, MCKNEE W, CARMICHAEL J AND SPURR NK. (1992). Relationship between the debrisoquine hydroxylase polymorphism and cancer susceptibility. Carcinogenesis, 13, 1035-1038.